ACELYRIN is a technology company.
ACELYRIN is a technology company.
ACELYRIN has raised $558.0M across 3 funding rounds.
ACELYRIN has raised $558.0M in total across 3 funding rounds.
ACELYRIN has raised $558.0M in total across 3 funding rounds.
ACELYRIN's investors include Access Biotechnology, Atlas Venture, Contrary Capital, Mott Family Capital, Matthew McAviney, Robert Garland, venBio, Westlake Village BioPartners, Ron Pragides.
The premise of your query is incorrect: ACELYRIN is not a technology company, but rather a biopharma company[1][2].
ACELYRIN is a late-stage clinical biopharma company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines in immunology[1][2]. The company serves patients with immunological disorders by developing novel drug candidates designed to address unmet medical needs. Rather than building software or digital products, ACELYRIN's core mission centers on advancing pharmaceutical treatments through its clinical pipeline and therapeutic expertise.
The company is backed by OrbiMed Advisors, a prominent healthcare-focused private equity firm[1], which provides both capital and strategic support for drug development and commercialization efforts.
ACELYRIN's pipeline demonstrates focus in specialized therapeutic areas:
ACELYRIN operates within the broader trend of specialty biopharma consolidation, where private equity firms acquire and develop promising drug candidates that larger pharmaceutical companies may overlook. This model allows the company to focus resources on specific therapeutic areas—particularly immunology—where significant unmet patient needs exist. The timing aligns with increased investment in precision medicine and targeted immunological treatments.
ACELYRIN has raised $558.0M across 3 funding rounds. Most recently, it raised $300.0M Series C in September 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2022 | $300.0M Series C | Access Biotechnology, Atlas Venture, Contrary Capital, Mott Family Capital, Matthew McAviney, Robert Garland, venBio, Westlake Village BioPartners, Ron Pragides | |
| Nov 1, 2021 | $250.0M Series B | Contrary Capital, Mott Family Capital, Matthew McAviney, Robert Garland, venBio, Westlake Village BioPartners, Ron Pragides | |
| Dec 1, 2020 | $8.0M Series A | Contrary Capital, Mott Family Capital, Matthew McAviney, Robert Garland, Westlake Village BioPartners, Ron Pragides |